Xtalks is proud to be the official Media Partner for the Pan-Canadian Framework to Promote Clinical Research in Canada Summit,...
Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the "Company", "we" or "NYB"), offers a comprehensive drug discovery platform...
The following amendment has been made to the 'Subscription of New Ordinary Shares, Warrant Issue, PDMR Dealings' announcement released on...
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne...
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET...
VANCOUVER, BC / ACCESS Newswire / October 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a development-stage...
Black Book Launches Rapid-Response Polls Tracking Real-Time Impacts on Providers, Payers and Patients WASHINGTON, D.C. / ACCESS Newswire / October...
Cross-Stakeholder Initiative Standardizes Preliminary Confidentiality Practices Across Sponsors, CROs, and Sites COLUMBIA, Md., Oct. 1, 2025 /PRNewswire/ -- Advarra, the market...
Favorable End-of-Phase 2 meeting with U.S. FDA for FAPI-74 for GI cancers Primary and secondary endpoints met Alignment with FDA...
MESA, ARIZONA / ACCESS Newswire / October 1, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), an emerging developer of...
Secure, scalable, multi-cloud platform using federated learning aims to accelerate cancer discoveries and treatments SEATTLE, WASHINGTON / ACCESS Newswire /...
Study to accelerate access to brain-computer interface technology, using Apple Vision Pro, for people with ALS, spinal cord injury (SCI),...
Study to accelerate access to brain-computer interface technology, using Apple Vision Pro, for people with ALS, spinal cord injury (SCI),...
Prioritizes High-Value Approved Drugs in Multi-Billion-Dollar Markets to Accelerate CommercializationFuture Platform Expansion into CNS, Men's Health, and Anti-Nausea ESTERO, FL...
The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement1 with new...
Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a...
Pr. Yann Gouëffic and affiliates (FRANCE-PAD) cover ~8% of all CLTI cases in France BERKELEY, Calif, Oct. 01, 2025 (GLOBE...
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of...
Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and increased brain myelin volume, resulting...
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica...